AIM ImmunoTech (NYSEAMERICAN:AIM) Trading Up 0.3% – What’s Next?

Shares of AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) traded up 0.3% during mid-day trading on Wednesday . The company traded as high as $1.6638 and last traded at $1.58. 30,567 shares were traded during trading, a decline of 60% from the average session volume of 77,060 shares. The stock had previously closed at $1.5750.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on AIM shares. Maxim Group raised AIM ImmunoTech to a “strong-buy” rating in a research note on Friday, September 5th. Zacks Research upgraded AIM ImmunoTech from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 14th. Two investment analysts have rated the stock with a Strong Buy rating and one has assigned a Buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Strong Buy” and a consensus target price of $450.00.

AIM ImmunoTech Stock Performance

The company has a market cap of $4.28 million, a P/E ratio of -0.06 and a beta of 1.03. The business’s fifty day moving average is $2.45 and its two-hundred day moving average is $5.55.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in AIM ImmunoTech stock. Corient Private Wealth LLC acquired a new position in shares of AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 10,001 shares of the company’s stock, valued at approximately $87,000. Corient Private Wealth LLC owned 1.31% of AIM ImmunoTech as of its most recent SEC filing. Institutional investors own 12.02% of the company’s stock.

About AIM ImmunoTech

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).